GANX (Gain Therapeutics) Q4/FY2025 Earnings & Corporate Update

Market Cap: Micro cap Stage: Clinical (Phase 1b) Focus: Parkinson's disease, GBA1 mutations, allosteric small molecule therapies

The Numbers

• Net Loss FY2025: $20.2M ($0.61/share) vs $20.4M ($0.89/share) FY2024

• R&D Expenses: $10.2M (down from $10.8M)

• G&A Expenses: $8.5M (down from $9.6M)

• Cash Position: $20.8M as of 12/31/25 (up from $10.4M at year-end 2024)

Burn rate is roughly $18-19M/year. $20.8M in cash gives them about 12-13 months of runway from year-end, so they'll need to raise by early 2027 unless they find a partner or cut burn. They doubled their cash position year over year, likely from a raise in 2025.

Pipeline

Lead candidate is GT-02287, oral small molecule for Parkinson's disease. Allosteric GCase modulator, brain-penetrant.

• Phase 1b nine-month extension ongoing, 14 of 16 patients past Day 150

• MDS-UPDRS scores stable over 150 days. Stable is the keyword here. In Parkinson's, stable is actually good because the disease is degenerative. Patients should be getting worse, so flat is a win

• In patients with elevated GluSph in CSF, 81% average reduction after 90 days. That's strong target engagement in the CNS

• IND submission to FDA expected Q2 2026

• Phase 2 expected to begin Q3 2026

• Phase 1b full results expected Q4 2026

Backup asset GT-04686 is ready for IND-enabling studies. New chemical series, same GCase target, showed activity in both in vitro and in vivo models.

The Setup

This is a Parkinson's disease modification play, which is the holy grail of neuro. Nobody has cracked disease modification in PD yet. The GBA1/GCase angle is scientifically validated and has big pharma attention. Sanofi, Roche, and others are active in this space.

The biomarker data is encouraging. 81% GluSph reduction in CSF is real target engagement. Stable MDS-UPDRS at 150 days in a degenerative disease is directionally positive. But this is still Phase 1b with 16 patients. Long way to go.

Cash is tight. 12-13 months of runway means dilution is coming unless a partnership materializes. That's the risk.

Catalysts Ahead

• IND clearance (Q2 2026)

• Phase 2 initiation (Q3 2026)

• Phase 1b full results (Q4 2026)

• Conference presentations throughout 2026

M&A Score: 72/100. GCase/Parkinson's space has pharma interest, and the platform has multiple assets. But the data is still early, MCap is tiny, and cash is tight. A partnership is more likely than a buyout at this stage, but if the Phase 2 reads out well, the M&A conversation changes fast.

Growth Score: 35/100. Pre-revenue, Phase 1b, single lead asset in clinic, tight runway. No commercial infrastructure, no revenue path for years. This is pure binary clinical risk right now.

Tag: M&A Target. If someone wants to own the GCase Parkinson's platform, this is a buy-the-science bet. The standalone commercial path is years away and capital-intensive.